Investigators’ Update March 2009 Volume 1 Issue 1 Locate Georgia cancer trials: www.georgiacancertrials.org Find Georgia oncologists: www.georgiacore.org/directory Event Calendar: Early Stage Breast Cancer Study Georgia CORE GOG Consortium in Interim Analysis (EU 822-03) Membership Performance 4/15/09- Breast Cancer Working Group Ruth M. O’Regan, MD, Principal Investigator Georgia CORE’s Consortium has received Meeting 6:30pm and Amelia Zelnak, Medical Director, have provisional membership status from the announced that their randomized phase II trial Gynecologic Oncology Group. According to Sponsored by of preoperative docetaxel and capecitabine Donald G. Gallup, MD, Principal Investigator, this Monogram Biosciences given sequentially or concurrently for Her2 unique statewide Consortium offers Georgia negative breast cancers is in interim analysis and investigators the opportunity to open GOG trials Featured Presentation temporarily closed to accrual. The study is provided that the Consortium accrues at least 150 Measuring the Target sponsored by Georgia CORE and funded by membership points in specific categories during the – A Functional Sanofi-Aventis. year. Proteomic Approach to Personalized Medicine” 51 patients (64% of a projected 80 patients) Currently active members of the Georgia CORE from 7 sites in the CORE Research Network GOG Consortium, Mercer/Memorial University Panel Discussion have enrolled in the study. Participating sites and the Medical College of Georgia, are on target to Her2 Testing and include: Amos Cancer Center/Columbus accrue half of the points by mid-year, ensuring that Management of Small Regional, Augusta Oncology Associates, provisional membership status is maintained. The Her2+ Cancers Central Georgia Cancer Care, Dekalb sites are accruing a greater percentage of patients to Medical/Georgia Cancer Specialists, Emory high priority GOG studies. Mitchell Z. Berger, MD RSVP to Shaunta Winship Cancer Institute, Georgia Cancer has recently announced plans to open GOG studies Wright at Center for Excellence/Grady Health System, at the Georgia Cancer Center for Excellence at email@example.com Wellstar Health System/Northeast Georgia or 404-584-8697 Grady Health System. Oncology Centers. Preliminary results of the study were reported Figure 1 at San Antonio Breast Cancer Symposium in December of 2008. The report was the first of its kind co-authored by academic and community oncologists and clinical research professionals active in the Georgia CORE network including Drs. Gabram, Hermann, O’Regan, Schnell, Srinivasiah and Zelnak. 49% of the patients enrolled in the study at the time of the report were African American. Georgia CORE™ Her2 Over Expressing Early 50 Hurt Plaza Suite 704 Stage Breast Cancer Study Atlanta, GA 30303 Actively Accruing 404-523-8735 www.georgiacore.org ABX018, the neoadjuvant trial of Trastuzumab in firstname.lastname@example.org combination with dose-dense ABI007 (Abraxane) followed by Vinorelbine sponsored by Georgia CORE For study information contact: Georgia CORE is and funded by Abraxis, is actively accruing patients. generously supported Diane Hicklin-Coleman, MPA Research Director by the Georgia Cancer Currently 14 (28% of a projected 50 patients) have Coalition, Emory been enrolled from the following CORE Research 770-313-4055 404-588-4082 Winship Cancer Network sites: Dekalb Medical/Georgia Cancer Institute and Georgia Specialists, Emory/Winship Cancer Institute, Georgia email@example.com oncologists dedicated Cancer Center for Excellence/Grady Health System, to today’s cancer care Northeast Georgia Cancer Care, Piedmont and tomorrow’s Hospital/Peachtree Hematology Oncology cancer cure. Consultants.